Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inwards

Showing results (221-230 of 382) with videos related to

Pageof 39
Sort By:
American Journal of Clinical Pathology|February 10, 2018
Giant Cell Tumor of Bone in Patients 55 Years and Older: A Study of 34 PatientsCory J Broehm, Carrie Y Inwards, Alyaa Al-Ibraheemi, et al.
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
Leukemia & Lymphoma|July 7, 2007
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasoneLijo Simpson, Stephen M Ansell, Joseph P Colgan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 21, 2020
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic ExperienceArushi Khurana, Ivana N Micallef, Betsy R LaPlant, et al.
The American Journal of Surgical Pathology|August 16, 2016
Histologic Spectrum of Giant Cell Tumor (GCT) of Bone in Patients 18 Years of Age and Below: A Study of 63 PatientsAlyaa Al-Ibraheemi, Carrie Y Inwards, Riyam T Zreik, et al.
Leukemia & Lymphoma|September 27, 2019
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?Mattia Novo, Grzegorz S Nowakowski, Thomas M Habermann, et al.
Cancer|June 11, 2008
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupStephen M Ansell, David J Inwards, Kendrith M Rowland, et al.
Blood Cancer Journal|January 8, 2021
Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphomaAlessia Castellino, Aung M Tun, Yucai Wang, et al.
The American Journal of Surgical Pathology|May 16, 2020
Giant Cell Tumor of Bone With Cartilage Matrix: A Clinicopathologic Study of 17 CasesIva Brčić, Feisal Yamani, Carrie Y Inwards, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Pageof 39

Showing results (221-230 of 382) with videos related to

Sort By:
Pageof 39
American Journal of Clinical Pathology|February 10, 2018
Giant Cell Tumor of Bone in Patients 55 Years and Older: A Study of 34 PatientsCory J Broehm, Carrie Y Inwards, Alyaa Al-Ibraheemi, et al.
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
Leukemia & Lymphoma|July 7, 2007
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasoneLijo Simpson, Stephen M Ansell, Joseph P Colgan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 21, 2020
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic ExperienceArushi Khurana, Ivana N Micallef, Betsy R LaPlant, et al.
The American Journal of Surgical Pathology|August 16, 2016
Histologic Spectrum of Giant Cell Tumor (GCT) of Bone in Patients 18 Years of Age and Below: A Study of 63 PatientsAlyaa Al-Ibraheemi, Carrie Y Inwards, Riyam T Zreik, et al.
Leukemia & Lymphoma|September 27, 2019
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?Mattia Novo, Grzegorz S Nowakowski, Thomas M Habermann, et al.
Cancer|June 11, 2008
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupStephen M Ansell, David J Inwards, Kendrith M Rowland, et al.
Blood Cancer Journal|January 8, 2021
Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphomaAlessia Castellino, Aung M Tun, Yucai Wang, et al.
The American Journal of Surgical Pathology|May 16, 2020
Giant Cell Tumor of Bone With Cartilage Matrix: A Clinicopathologic Study of 17 CasesIva Brčić, Feisal Yamani, Carrie Y Inwards, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Pageof 39